Product Description
Mechanisms of Action: FLAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Coronary Syndrome|Angina, Unstable|Angina, Stable
Phase 2: Myocardial Infarction|Coronary Artery Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-002145-39 |
2005-002145-39 | P2 |
Completed |
Myocardial Infarction |
2005-12-14 |
2022-03-12 |
Treatments |
|
2004-004980-30 |
2004-004980-30 | P2 |
Completed |
Coronary Artery Disease |
2005-03-14 |
2022-03-12 |
Treatments |
|
NCT00353067 |
The LTCAD Study | P3 |
Suspended |
Acute Coronary Syndrome|Angina, Unstable|Angina, Stable |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|